רווח למניה בשנים עשר החודשים האחרונים: OS Therapies Inc. (OSTX)

OS Therapies Incorporated focuses on developing targeted immunotherapies to combat osteosarcoma through R&D. The fundamental TTM net income per share metric visualizes the financial dynamics, where the value -1.04 shows the current figure. The company's environmental responsibility is evident in its chemical waste recycling, while unique research into rare bone pathologies creates potential for market dominance.

Net income per share (TTM) measures the portion of total income attributable to a single security over one year, excluding dilution from issuance. For OS Therapies Incorporated (OSTX), this metric reflects the financing efficiency of developing targeted cancer therapies. By analyzing the 12-month earnings per share history, an investor assesses the impact of pipeline diversification on capitalization. This trend captures the business's resilience to clinical trial risks, serving as a key criterion for the fundamental valuation of asset quality.